JP Morgan Chase’s DA32 Life Science Tech Acquisition Corp. Class A Common Stock DALS Stock Holding History

JP Morgan Chase’s Portfolio DALS Stock Details DALS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-250,000	Closed	-$2.53M	–	7480
2023 Q1	$2.53M	Buy	250,000 +175,000	+233%	+$1.76M	﹤0.01%	3368
2022 Q4	$750K	Sell	75,000 -24,500	-25%	-$241K	﹤0.01%	4248
2022 Q3	$964K	Sell	99,500 -50,500	-34%	-$491K	﹤0.01%	4035
2022 Q2	$1.45M	Hold	150,000	–	–	﹤0.01%	3813
2022 Q1	$1.46M	Sell	150,000 -139,000	-48%	-$1.34M	﹤0.01%	4008
2021 Q4	$2.83M	Sell	289,000 -10,349	-3%	-$101K	﹤0.01%	3551
2021 Q3	$2.94M	Buy	+299,349	New	+$2.96M	﹤0.01%	3470

Other funds holding DALS

FTCM

First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

MCM

Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase's DALS Position: Q2 2023 in Review

JP Morgan Chase sold out of DA32 Life Science Tech Acquisition Corp. Class A Common Stock (DALS) in Q2 2023, closing a stake of 250,000 shares — an estimated $2.53M sold.

JP Morgan Chase first reported a position in DALS in Q3 2021 and held it in 7 quarters. The position peaked at $2.94M in Q3 2021. 50 funds tracked by Wall St. Rank hold DALS as of Q2 2023.

JP Morgan Chase reported no remaining DA32 Life Science Tech Acquisition Corp. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
JP Morgan Chase sold 250,000 DA32 Life Science Tech Acquisition Corp. Class A Common Stock shares in Q2 2023, an estimated $2.53M.
JP Morgan Chase first reported a position in DA32 Life Science Tech Acquisition Corp. Class A Common Stock in Q3 2021 and held it in 7 quarters.
JP Morgan Chase's DA32 Life Science Tech Acquisition Corp. Class A Common Stock position peaked at $2.94M in Q3 2021.
50 funds tracked by Wall St. Rank held DA32 Life Science Tech Acquisition Corp. Class A Common Stock as of Q2 2023.

Based on JP Morgan Chase's 13F filing for Q2 2023, filed 11 Aug 2023.